Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 13, 2026 07:30 ET | Source: PMGC Holdings Inc.

NorthStrive Biosciences Announces U.S. Arrival of EL-32 Working Cell Bank and Initiation of Manufacturing Optimization for Dual Myostatin Assets Targeting Muscle Preservation with GLP-1 Therapies in Collaboration with Modulant Biosciences

NorthStrive Biosciences Announces U.S. Arrival of EL-32 Working Cell Bank and Initiation of Manufacturing Optimization for Dual Myostatin Assets Targeting
April 08, 2026 07:30 ET | Source: PMGC Holdings Inc.

PMGC Holdings Inc. [NASDAQ: ELAB] Fully Utilizes All Available in $20M Equity Financing Facility, Strengthens Cash Position and Advances Multi-Sector Acquisition Strategy

PMGC Holdings Inc. [NASDAQ: ELAB] PMGC Holdings Fully Utilizes All Available in $20M Equity Financing Facility, Strengthens Cash Position and Advances Mult
March 30, 2026 07:03 ET | Source: PMGC Holdings Inc.

PMGC Holdings Inc. [NASDAQ: ELAB] Reports 2025 Annual Results and Files Form 10-K, Company Expands Asset Base to $13.8M, a 43% Increase from 2024

PMGC Holdings Inc. [NASDAQ: ELAB] Reports 2025 Annual Results and Files Form 10-K, Company Expands Asset Base to $13.8M, a 43% Increase from 2024
March 27, 2026 16:05 ET | Source: PMGC Holdings Inc.

NorthStrive Biosciences Signs Licensing Agreement Amendment with MOA Life Plus [KOSDAQ: 142760] for Dual Myostatin Assets Targeting Muscle Preservation in Combination with GLP-1 Treatments

NorthStrive Biosciences Signs Licensing Agreement Amendment with MOA Life Plus [KOSDAQ: 142760] for Dual Myostatin Assets Targeting Muscle Preservation in
March 10, 2026 07:30 ET | Source: PMGC Holdings Inc.

NorthStrive Biosciences Announces Launch of EL-32 Preclinical Study Evaluating Muscle Preservation in GLP-1 Weight Loss Therapy

Northstrive Biosciences Announces Launch of EL-32 Preclinical Study Evaluating Muscle Preservation in GLP-1 Weight Loss Therapy
February 19, 2026 07:30 ET | Source: PMGC Holdings Inc.

NorthStrive Biosciences Files 10 U.S. Patent Applications for EL-22 and EL-32 Targeting Muscle Growth and Yield Enhancement in Farmed Animals

NorthStrive Biosciences Files 10 U.S. Patent Applications for EL-22 and EL-32 Targeting Muscle Growth and Yield Enhancement in Farmed Animals
February 11, 2026 07:30 ET | Source: PMGC Holdings Inc.

NorthStrive Biosciences Signs Definitive License Agreement for Commercialization of EL-22 and EL-32, a Myostatin-Engineered Probiotic for Muscle Preservation in Animal Health

NorthStrive Biosciences Signs Definitive License Agreement for Commercialization of EL-22 and EL-32, a Myostatin-Engineered Probiotic for Muscle Preservati
February 04, 2026 16:30 ET | Source: PMGC Holdings Inc.

NorthStrive Biosciences Announces Progress Updates to Phase III Timeline for AI-Driven Drug Discovery Program with Yuva Biosciences

NorthStrive Biosciences Announces Progress Updates to Phase III Timeline for AI-Driven Drug Discovery Program with Yuva Biosciences
January 22, 2026 08:00 ET | Source: Corxel Pharmaceuticals

CORXEL Announces $287 million Series D1 Financing to Further Advance Its Cardiometabolic Pipeline including Oral Small Molecule GLP-1 Receptor Agonist

Series D1 financing with participation from a syndicate of global healthcare-focused investors, including RTW Investments, SR One Capital Management (SR One), TCG Crossover (TCGX), RA Capital...
August 27, 2025 08:05 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics to Participate in Upcoming Investor Conferences

Kailera Therapeutics announced participation in upcoming investor conferences.